Merck Fosamax patent upheld
Executive Summary
Merck's Fosamax (alendronate) will not face generic competition until at least August 2007, following a decision by Wilmington, Del., federal court to uphold a method of use patent for the osteoporosis drug Nov. 4. Teva intends to appeal the decision...